Australian TB expert welcomes new rapid test
Friday 10 December 2010
AUSTRALIAN TB EXPERT WELCOMES NEW RAPID TB TEST
Novel test cuts diagnosis time down from 3-6 weeks to less than 2 hours
The World Health Organization (WHO) has endorsed a new and novel rapid test for tuberculosis (TB) which could provide an accurate diagnosis for many patients in about 100 minutes compared to current tests that can take up to three to six weeks. TB is a major cause of death and disability in the regions closes to us so it remains a real risk to the Australian community.
World TB expert Warwick Britton from the Centenary Institute in Sydney said: “The current test is over 100 years old now so it poses a major limitation in the early diagnosis of TB, especially in children and those with drug-resistant TB. This new rapid test is a significant breakthrough because it will allow accurate diagnosis within hours rather than the three to six weeks it currently takes to grow the bacterium.”
Professor Britton added: “It will be a challenge to introduce this technology into high burden countries in Asia and the Pacific but Australian medical scientists could collaborate with colleagues in these countries to assist in this process. The Mycobacterial Research Laboratory at the Centenary Institute, for example, has an ongoing collaboration with the National TB Program in Vietnam so we will be able to assist in this type of technology transfer.”
WHO's endorsement of the rapid test, which is a fully automated NAAT (nucleic acid amplification test) follows 18 months of rigorous assessment of its field effectiveness in the early diagnosis of TB, as well as multidrug-resistant TB (MDR-TB) and TB complicated by HIV infection, which are more difficult to diagnose.
Evidence to date indicates that implementation of this test could result in a three-fold increase in the diagnosis of patients with drug-resistant TB and a doubling in the number of HIV-associated TB cases diagnosed in areas with high rates of TB and HIV.
Many countries still rely principally on sputum smear microscopy, a diagnostic method that was developed over a century ago. But this new 'while you wait' test incorporates modern DNA technology that can be used outside of conventional laboratories. It also benefits from being fully automated and therefore easy and safe to use.
WHO is now calling for the fully automated NAAT to be rolled out under clearly defined conditions and as part of national plans for TB and MDR-TB care and control. Policy and operational guidance are also being issued based on findings from a series of expert reviews and a global consultation held last week in Geneva. The consultation was attended by more than 100 representatives from national programmes, development aid agencies and international partners.
Affordability has been a key concern in the assessment process. Co-developer FIND (the Foundation for Innovative and New Diagnostics) is announcing today it has negotiated with the manufacturer, Cepheid, a 75% reduction in the price for countries most affected by TB, compared to the current market price. Preferential pricing will be granted to 116 low- and middle-income countries where TB is endemic, with additional reduction in price once there is significant volume of demand.
"There has been a strong commitment to remove any obstacles, including financial barriers, that could prevent the successful roll-out of this new technology," said Dr Giorgio Roscigno, FIND's Chief Executive Officer. "For the first time in TB control, we are enabling access to state-of-the-art technology simultaneously in low, middle and high income countries. The technology also allows testing of other diseases, which should further increase efficiency."
WHO is also releasing recommendations and guidance for countries to incorporate this test in their programs. This includes testing protocols (or algorithms) to optimize the use and benefits of the new technology in those persons where it is needed most.
Though there have been major improvements in TB care and control, tuberculosis killed an estimated 1.7 million people in 2009 and 9.4 million people developed active TB last year.
– ends –
Media Contact: Tanya Sarina, Communications Manager at the Centenary Institute
p: 02 9565 6228 m: 0431 029 215 e: email@example.com
About the Centenary Institute: The Centenary Institute is an independent medical research institute, affiliated with Royal Prince Alfred Hospital and the University of Sydney. Our unique blend of highly skilled staff and state-of-the art equipment and facilities has allowed us to become world leaders in three critical areas of medical research – cancer, cardiovascular disease and infectious diseases. For further information about the Centenary Institute, visit www.centenary.org.au